EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study

Cuie Chang, Sha Lv, Lingyan Yu, Lingcheng Xu, Donghang Xu, Haibin Dai, Junjun Xu iD

Journal of Cardiovascular Pharmacology and Therapeutics · 2026

DOI: 10.1177/10742484261490639 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2026. Verfasst von Cuie Chang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Atrial Fibrillation, Dabigatran, Rivaroxaban, Stroke. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Clinical Pharmacy Special Committee of Zhejiang Medical Doctor Association, Clinical Medicine Special Fund Project of Zhejiang Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate adherence to four direct oral anticoagulants (DOACs) and its influencing factors in patients with non-valvular atrial fibrillation (NVAF), providing evidence for strategies to improve adherence.

Methods

A retrospective cohort study included NVAF patients initiating DOAC therapy at a tertiary hospital (January 2016–November 2023). Adherence was evaluated using the proportion of days covered (PDC), with PDC ≥ 0.8 defined as good adherence. Adherence levels for dabigatran, rivaroxaban, apixaban, and edoxaban were compared at 3, 6, 9, and 12 months. Logistic regression identified factors influencing 1-year adherence, assessing the impact of initiation year and the National Volume-Based Drug Procurement (NVBP) policy.

Results

A total of 1,150 NVAF patients were enrolled (dabigatran: n = 401; rivaroxaban: n = 656; apixaban: n = 18; edoxaban: n = 75),In this main cohort, overall adherence progressively declined, with only 40.78% achieving PDC ≥ 0.8 at 1 year. Significant differences existed among groups (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDabigatranRivaroxabanStrokePyridonesFactor Xa InhibitorsMedication AdherenceAntithrombinsHumansRetrospective StudiesFemaleMaleAgedAdministration, OralAged, 80 and overThiazolesPyridinesTime FactorsPyrazolesMiddle AgedRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

Chinadirect oral anticoagulantsinfluencing factorsmedication adherencenon-valvular atrial fibrillation

Substanzen

DabigatranThiazolesRivaroxabanPyridonesapixabanFactor Xa InhibitorsPyridinesPyrazolesedoxabanAntithrombins

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Pharmacy, Zhejiang Hospital, Hangzhou, China.

ORCID-Profile: Junjun Xu

Förderung

  • Clinical Pharmacy Special Committee of Zhejiang Medical Doctor Association
  • Clinical Medicine Special Fund Project of Zhejiang Medical Association

Zitieren

APA

Chang, C., Lv, S., Yu, L., Xu, L., Xu, D., Dai, H., & Xu, J. (2026). Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484261490639

Vancouver

Chang C, Lv S, Yu L, Xu L, Xu D, Dai H, et al. Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study. Journal of Cardiovascular Pharmacology and Therapeutics. 2026. doi:10.1177/10742484261490639

BibTeX
@article{Chang2026,
  author = {Chang, Cuie and Lv, Sha and Yu, Lingyan and Xu, Lingcheng and Xu, Donghang and Dai, Haibin and Xu, Junjun},
  title = {Adherence to Direct Oral Anticoagulants in Patients With Non-valvular Atrial Fibrillation: A Single-Center Retrospective Study},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2026},
  doi = {10.1177/10742484261490639}
}
Kostenlos starten →